AIM ImmunoTech Inc

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Locally Advanced Pancreatic Adenocarcinoma and the unmet need.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) as a potential treatment for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a powerful synergistic effect, leading the investigator to conclude that the combination therapy could be far more effective than pembrolizumab alone as a therapy for the disease.

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Inc. (NYSE:AIM ) Q4 2023 Earnings Conference Call April 2, 2024 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer Dr. Christopher McAleer - Scientific Officer Conference Call Participants James Molloy - Alliance Global Partners Ed Woo - Ascendiant Capital Markets Operator Hello. And welcome to the AIM ImmunoTech Fiscal Year 2023 Update Conference Call and Webcast.

AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript

Year marked by growing body of promising data demonstrating Ampligen's potential to address multiple high-value indications

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K.

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference

Aimia Inc. (AIMFF) Q4 2023 Earnings Call Transcript

OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company's Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET.

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ET Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ET

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties the ability to ask questions and submit topics for future videos Access the AIM CEO Corner Here! OCALA, Fla.

AIM ImmunoTech Announces Launch of CEO Corner Platform

Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen's potential to address multiple high-value indications OCALA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent accomplishments and provided a business outlook.

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

Phase 1b portion of the study expected to be completed within six months Phase 1b portion of the study expected to be completed within six months

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

OCALA, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has received authorization from the Erasmus Medical Center (“Erasmus MC”) Ethics Committee to open a European site for the ongoing Phase 2 study (“AMP-270”) of Ampligen as a therapy for locally advanced pancreatic cancer.

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca's Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that enrollment is open at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining AIM's Ampligen® (rintatolimod) with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of pancreatic cancer (the “DURIPANC Study”).

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that shareholders have elected all four of the Company's directors, Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels and William M. Mitchell, at the Company's 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) held today. AIM issued the following statement: “We would like to thank our shareholders for their support and engagement throughout this process. Our Board.

AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting

Court Found that Several AIM Advance Notice Bylaws Are Invalid NEW YORK , Jan. 3, 2024 /PRNewswire/ -- Ted D. Kellner, Todd Deutsch and Robert L.

Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the Delaware Court of Chancery (the “Court”) ruled that the nomination notice (the “Notice”) submitted by a member of a group of individuals who are seeking to nominate three candidates for election to AIM's four-person Board of Directors (the “Board”) (collectively, the “Activist Group”) was properly rejected for being invalid under the Company's Bylaws. This ruling follows a trial h.

Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board's Determination that Activist Group's Nominations Are Invalid

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company will convene its upcoming 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) as planned on December 1, 2023, and will then adjourn proceedings, without conducting any other business, until December 29, 2023. The purpose of the adjournment is to provide the Delaware Court of Chancery (the “Court”) with sufficient time to issue a ruling with respect to the.

AIM ImmunoTech Provides Update Regarding Annual Meeting

Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No.

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents

No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the last subject has completed treatment in the Company's Phase 2 study evaluating Ampligen® as a potential therapeutic for people with the Post-COVID condition of fatigue (“AMP-518”).

AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. (NYSE:AIM ) Q3 2023 Earnings Call Transcript November 15, 2023 8:00 AM ET Company Participants Thomas Equels - Executive Vice Chairman, Chief Executive Officer and President Christopher McAleer - Scientific Officer Conference Call Participants Edward Woo - Ascendiant Capital Operator Hello, and welcome to the AIM ImmunoTech Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

AIM ImmunoTech Inc. (AIM) Q3 2023 Earnings Call Transcript

– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will host conference call and webcast today, November 15 th at 8:30 AM ET OCALA, Fla., Nov. 15, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter 2023 and provided a business update.

News for AIM ImmunoTech Inc Stock (AIM)